3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Breast
1
Conditions
Breast Neoplasms
2
Ventricular Dysfunction, Left
1
Lymphoma, Large B-Cell, Diffuse
1
Cardiotoxicity
1
Interventions
Trastuzumab
8
Doxorubicin
8
Exercise
6
Cyclophosphamide
6
Echocardiography
5
Carvedilol
5
Docetaxel
4
Tablets
2
Silymarin
2
Radiotherapy
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Exercise Test
2
Epirubicin
2
Bisoprolol
2
Atorvastatin
2
Anthracyclines
2
sacubitril and valsartan sodium hydrate drug combination
1
nicotinamide-beta-riboside
1
mitoquinone
1
epicatechin gallate
1
empagliflozin
1
dapagliflozin
1
candesartan
1
Watchful Waiting
1
Therapeutics
1
Taxes
1
Tamoxifen
1
Social Determinants of Health
1
Secondary Prevention
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiotoxicity
×
Nebivolol
×
Breast
×
Clear all
NCT05728632
2023-02-23
CONTROL
Humanitas Hospital, Italy
Phase 3
Unknown
80 enrolled